These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 30463996)

  • 1.
    Sanchez-Vega F; Hechtman JF; Castel P; Ku GY; Tuvy Y; Won H; Fong CJ; Bouvier N; Nanjangud GJ; Soong J; Vakiani E; Schattner M; Kelsen DP; Lefkowitz RA; Brown K; Lacouture ME; Capanu M; Mattar M; Qeriqi B; Cecchi F; Tian Y; Hembrough T; Nagy RJ; Lanman RB; Larson SM; Pandit-Taskar N; Schöder H; Iacobuzio-Donahue CA; Ilson DH; Weber WA; Berger MF; de Stanchina E; Taylor BS; Lewis JS; Solit DB; Carrasquillo JA; Scaltriti M; Schultz N; Janjigian YY
    Cancer Discov; 2019 Feb; 9(2):199-209. PubMed ID: 30463996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Afatinib and Lapatinib Against
    Nakata S; Fujita M; Nakanishi H
    Anticancer Res; 2019 Nov; 39(11):5927-5932. PubMed ID: 31704817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.
    Kwak EL; Ahronian LG; Siravegna G; Mussolin B; Borger DR; Godfrey JT; Jessop NA; Clark JW; Blaszkowsky LS; Ryan DP; Lennerz JK; Iafrate AJ; Bardelli A; Hong TS; Corcoran RB
    Cancer Discov; 2015 Dec; 5(12):1271-81. PubMed ID: 26432108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
    Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
    BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
    Kim J; Fox C; Peng S; Pusung M; Pectasides E; Matthee E; Hong YS; Do IG; Jang J; Thorner AR; Van Hummelen P; Rustgi AK; Wong KK; Zhou Z; Tang P; Kim KM; Lee J; Bass AJ
    J Clin Invest; 2014 Dec; 124(12):5145-58. PubMed ID: 25401468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Torigoe H; Shien K; Takeda T; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Sakaguchi M; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Cancer Sci; 2018 May; 109(5):1493-1502. PubMed ID: 29532558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma.
    Gambardella V; Fleitas T; Tarazona N; Cejalvo JM; Gimeno-Valiente F; Martinez-Ciarpaglini C; Huerta M; Roselló S; Castillo J; Roda D; Cervantes A
    Ann Oncol; 2019 Aug; 30(8):1254-1264. PubMed ID: 31046106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.
    Apicella M; Migliore C; Capelôa T; Menegon S; Cargnelutti M; Degiuli M; Sapino A; Sottile A; Sarotto I; Casorzo L; Cassoni P; De Simone M; Comoglio PM; Marsoni S; Corso S; Giordano S
    Oncogene; 2017 Mar; 36(9):1200-1210. PubMed ID: 27524418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.
    Lennerz JK; Kwak EL; Ackerman A; Michael M; Fox SB; Bergethon K; Lauwers GY; Christensen JG; Wilner KD; Haber DA; Salgia R; Bang YJ; Clark JW; Solomon BJ; Iafrate AJ
    J Clin Oncol; 2011 Dec; 29(36):4803-10. PubMed ID: 22042947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
    Porth I; Hirsch D; Ceribas Y; Weidner P; Weichert W; Götze TO; Perner S; Luley K; Heyer CM; de la Torre C; Hofheinz RD; Lorenzen S; Gaiser T
    Eur J Cancer; 2023 Apr; 183():119-130. PubMed ID: 36848831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.
    Jørgensen JT
    World J Gastroenterol; 2014 Apr; 20(16):4526-35. PubMed ID: 24782605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
    Maron SB; Chatila W; Walch H; Chou JF; Ceglia N; Ptashkin R; Do RKG; Paroder V; Pandit-Taskar N; Lewis JS; Biachi De Castria T; Sabwa S; Socolow F; Feder L; Thomas J; Schulze I; Kim K; Elzein A; Bojilova V; Zatzman M; Bhanot U; Nagy RJ; Lee J; Simmons M; Segal M; Ku GY; Ilson DH; Capanu M; Hechtman JF; Merghoub T; Shah S; Schultz N; Solit DB; Janjigian YY
    Clin Cancer Res; 2023 Sep; 29(18):3633-3640. PubMed ID: 37406106
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Zhang L; Hamdani O; Gjoerup O; Cho-Phan C; Snider J; Castellanos E; Nimeiri H; Frampton G; Venstrom JM; Oxnard G; Klempner SJ; Schrock AB
    JCO Precis Oncol; 2022 Jan; 6():e2100330. PubMed ID: 35050711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET as resistance factor for afatinib therapy and motility driver in gastric cancer cells.
    Ebert K; Mattes J; Kunzke T; Zwingenberger G; Luber B
    PLoS One; 2019; 14(9):e0223225. PubMed ID: 31557260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
    Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
    Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.
    Shitara K; Bang YJ; Iwasa S; Sugimoto N; Ryu MH; Sakai D; Chung HC; Kawakami H; Yabusaki H; Sakamoto Y; Nishina T; Inaki K; Kuwahara Y; Wada N; Suto F; Arita T; Sugihara M; Tsuchihashi Z; Saito K; Kojima A; Yamaguchi K
    Nat Med; 2024 Jul; 30(7):1933-1942. PubMed ID: 38745009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
    Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
    Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.